	Sequentail	BQT		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events Total	Events Tota	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	ABCDEFG
Kefeli A 2016	113 130	114 130	45.9%	0.93 [0.45, 1.94]	-	• • • •
Liu 2014	160 179	165 178	54.1%	0.66 [0.32, 1.39]		$\bullet \bullet \bullet \bullet \bullet \bullet \bullet$
Total (95% CI) Total events	309 273	308 279	100.0%	0.79 [0.47, 1.32]	•	
Heterogeneity: Chi ² = 0.41, df = 1 (P = 0.52); l ² = 0%						
Test for overall effect: Z = 0.91 (P = 0.36)					0.01 0.1 1 10 BQT Sequential	100

Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Supplementary Fig. 4. Forest plot comparing the different therapies in terms of the eradication rates between sequential therapy. (A) Intention-to-treat analysis. (B) Per protocol analysis. BQT, bismuth quadruple therapy; M-H, Mantel-Haenszel test.